*From the Authors*:

We thank Dr. Shekar and Dr. Schmidt for their letter regarding our recent publication ([@bib1]). They raise important questions about the clinical impact and potential drawbacks of the near-apneic protocol tested in our study.

Regarding intrapulmonary shunt, we measured it at the end of the experiment (data not shown) and found no differences between the near-apneic group and the group ventilated with conventional protective ventilation, which suggests that near-apneic ventilation did not promote further atelectasis. Moreover, in the near-apneic ventilation, the contribution of the native lungs to oxygenation was significant by the end of the experiment, as indicated by oxygen tensions of 78 ± 4 mm Hg in the mixed venous blood and 300 ± 31 mm Hg in the arterial blood.

As pointed out in the D[iscussion]{.smallcaps} of our study, we agree with Dr. Shekar and Dr. Schmidt in that applying very low respiratory rates and V[t]{.smallcaps} during near-apneic ventilation may require deep sedation and neuromuscular blockade, which ideally should be avoided. However, observational studies have shown that during the first 3 days after connection to extracorporeal membrane oxygenation, most patients with acute respiratory distress syndrome are deeply sedated and paralyzed, even if they are not receiving near-apneic ventilation ([@bib2], [@bib3]).

To overcome these controversies, we now need clinical studies to identify the optimal ventilatory strategies for patients with acute respiratory distress syndrome connected to extracorporeal membrane oxygenation.
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